X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Abbvie expands neuroscience pipeline with multiple clinical-stage and preclinical candidates, including CVL-231 (emraclidine), with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $8,700.0 million Upfront Cash: $8,700.0 million
Deal Type: Acquisition December 06, 2023
Details:
The findings further demonstrate the emerging role the neuroimmune axis may play in the development of schizophrenia and in providing a platform for schizophrenia drug discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Herophilus
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Emraclidine is a positive allosteric modulator designed to selectively target the M4 muscarinic receptor subtype. Emerging evidence suggests that activation of M4 muscarinic acetylcholine receptor subtypes can reduce striatal dopamine signaling and reduce psychotic symptoms.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
CVL-231 (emraclidine), is a positive allosteric modulator designed to selectively target the M4 muscarinic receptor subtype. Emerging evidence suggests that activation of M4 muscarinic acetylcholine receptor subtypes can reduce striatal dopamine signaling.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Cerevel intends to use the net proceeds to accelerate market development and pre-commercial planning activities for emraclidine and tavapadon, to advance the remainder of the programs in its pipeline, including darigabat, and its other promising earlier-stage programs.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley & Co
Deal Size: $254.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 12, 2022
Details:
Cerevel intends to use the net proceeds to support the continued development of emraclidine, including to accelerate registration-enabling activities, to evaluate the potential of emraclidine in other populations, including Alzheimer’s disease psychosis.
Lead Product(s): Emraclidine
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-231
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 10, 2022
Details:
Cerevel will present data demonstrating consistent clinical pharmacology across a wide range of doses of tavapadon in several Phase 1 clinical trials, supporting its potential as a promising next-generation treatment for Parkinson’s disease.
Lead Product(s): Tavapadon
Therapeutic Area: Neurology Product Name: CVL-751
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Emraclidine now the international nonproprietary name for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia. Company expects to initiate Phase 2 program by the middle of 2022, with data expected in the first half of 2024.
Lead Product(s): CVL-231
Therapeutic Area: Psychiatry/Psychology Product Name: PF-06852231
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
CVL-871, a dopamine D1/D5 receptor partial agonist in development for the treatment of dementia-related apathy, and provide an update on CVL-231, a muscarinic M4 positive allosteric modulator in development for the treatment of schizophrenia.
Lead Product(s): CVL-871
Therapeutic Area: Psychiatry/Psychology Product Name: CVL-871
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
Cerevel Therapeutics' lead drug Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolerability profile.
Lead Product(s): Tavapadon
Therapeutic Area: Neurology Product Name: CVL-751
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities LLC
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
